Cargando…
Comparative efficacy and safety of oral P2Y(12) inhibitors after non-ST-elevation acute coronary syndromes: a network meta-analysis
BACKGROUND: Currently, potent P2Y(12) inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of prasugrel over ticagrelor in patients with non-ST-elevation ACS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014125/ https://www.ncbi.nlm.nih.gov/pubmed/35428703 http://dx.doi.org/10.1136/openhrt-2021-001937 |